Tu1737 ROLE OF NLRX1 AGONIST NX-13 IN REDUCING VISCERAL HYPERSENSITIVITY IN PRECLINICAL GASTROINTESTINAL INFLAMMATION
Silvio Danese(IRCCS Ospedale San Raffaele), Bram Verstockt(KU Leuven), Fabio Cataldi(Pfizer (United States)), Remo Panaccione, Laurent Peyrin‐Biroulet(Délégation Centre-Est), Séverine Vermeire(KU Leuven), Rebecca Mosig, Andrés Yarur(Cedars-Sinai Medical Center)
Cited by 0
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k